Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 08-03 19:04:32时区推断·⟳ 抓取 08-03 19:05:49·⚡ 决策 08-04 09:15:58 +14h10m·84.5 天前
OPKO向Cocrystal Pharma投资500万美元认购约547.4万股
500万美元融资相当于Cocrystal约1296万美元市值的近四成，补充现金本身偏正面。
📄 原文Investing.com↗ 原文
OPKO Health invests $5 million in Cocrystal Pharma
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks BOTHELL, Wash. - Cocrystal Pharma, Inc. (NASDAQ…
不做 Cocrystal Pharma（COCP.US）
融资利好已在事件日放量上涨中反映，且下一实质临床数据在2026年四季度，盘后追多不做。
不做 OPKO Health（OPK.US）
500万美元投资相对OPKO体量太小，且只是增加既有关联持股，不构成OPK.US交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 盘前披露OPKO以0.9134美元/股认购COCP约547.4万股。市场反应:COCP.US事件日收涨约14.6%，现价约0.93美元。
关键理由
- 500万美元融资相当于Cocrystal约1296万美元市值的近四成，补充现金本身偏正面。
- 认购价0.9134美元接近成交日报价且无认股权证，稀释条款不算恶劣。
- 核心CDI-988诺如病毒项目仍在1b期，顶线数据预计到2026年四季度，短线基本面兑现仍远。
主要风险
- COCP.US日均成交额很低，事件日放量后次日追买滑点和回落风险高。
- OPKO与Cocrystal存在长期关联投资人关系，本次更像续命融资而非外部战略验证。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-03 · 影响 weakens
未见额外权证负担，但临床数据仍要到2026年四季度，短线不是数据读出催化。
检索:Cocrystal Pharma OPKO Health $5 million investment warrants dilution CDI-988 topline data 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,662 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
BOTHELL, Wash. - Cocrystal Pharma, Inc. (NASDAQ:COCP) received a $5 million investment from OPKO Health, Inc. (NASDAQ:OPK), according to a press release statement issued today.
Under the agreement, Cocrystal sold 5,474,053 shares of common stock to OPKO at $0.9134 per share, the Nasdaq Consolidated Bid Price on the trading day of closing. The transaction did not include warrants or other derivative securities.
The investment comes as Cocrystal advances its lead norovirus program, CDI-988, which is currently in a Phase 1b clinical trial. The company expects to report topline data from the trial by the end of the fourth quarter of 2026.
"OPKO’s increased investment reflects the confidence of one of our most steadfast supporters as we approach a defining moment for Cocrystal," said James Sapirstein, Chief Executive Officer of Cocrystal Pharma.
Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health and co-founder, director and principal stockholder of Cocrystal, stated: "This additional investment reflects our continued conviction in Cocrystal’s science and its path forward."
Cocrystal is a clinical stage biotechnology company developing antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses, and hepatitis C viruses.
The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and were not registered under the Securities Act or applicable state securities laws.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOTHELL, Wash. - Cocrystal Pharma, Inc. (NASDAQ:COCP) received a $5 million investment from OPKO Health, Inc. (NASDAQ:OPK), according to a press release statement issued today.
Under the agreement, Cocrystal sold 5,474,053 shares of common stock to OPKO at $0.9134 per share, the Nasdaq Consolidated Bid Price on the trading day of closing. The transaction did not include warrants or other derivative securities.
The investment comes as Cocrystal advances its lead norovirus program, CDI-988, which is currently in a Phase 1b clinical trial. The company expects to report topline data from the trial by the end of the fourth quarter of 2026.
"OPKO’s increased investment reflects the confidence of one of our most steadfast supporters as we approach a defining moment for Cocrystal," said James Sapirstein, Chief Executive Officer of Cocrystal Pharma.
Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health and co-founder, director and principal stockholder of Cocrystal, stated: "This additional investment reflects our continued conviction in Cocrystal’s science and its path forward."
Cocrystal is a clinical stage biotechnology company developing antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses, and hepatitis C viruses.
The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and were not registered under the Securities Act or applicable state securities laws.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。